Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 2:38 AM
Ignite Modification Date:
2025-12-26 @ 1:16 AM
NCT ID:
NCT02660034
Group ID:
EG012
Title:
Part B: Dose Expansion Phase - Arm 7
Description:
Participants with advanced or metastatic pancreatic adenocarcinoma treated with at least 1 but no more than 2 prior lines of therapy received tislelizumab 200 mg IV Q3W + pamiparib 40 mg orally twice daily. At least 1 prior treatment for advanced or metastatic disease must have contained a platinum agent. Any potential participant with a known deleterious germline or somatic BRCA was eligible even if platinum-naïve.
Deaths Number Affected:
20
Deaths Number At Risk:
None
Serious Number Affected:
8
Serious Number At Risk:
21
Other Number Affected:
18
Other Number At Risk:
21
Study:
NCT02660034
Results Section:
NCT02660034
Adverse Events Module:
NCT02660034